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EPOXYKETONE-BASED
IMMUNOPROTEASOME INHIBITORS

-continued

FIELD OF THE INVENTION

The present method relates to epoxyketone-based immu
noproteasome inhibitors and, in particular, to the synthesis of
the inhibitors, their intermediaries, and treatment of disease

using the inhibitors.
Eponemycin (2)
BACKGROUND OF THE INVENTION

Intracellular protein degradation is a highly regulated pro
cess in Which proteins are ?rst targeted for degradation by
conjugation to ubiquitin, a 76 amino acid polypeptide. Ubiq
uitinated proteins are then recogniZed by the 19S regulatory
domain of the 26S proteasome. Through a series of ATP
hydrolysis-dependent processes, targeted proteins are deu
biquitinated and threaded into the core proteolytic complex,
the 20S proteasome, Where they are degraded into small pep

20

Dihydroeponemycin (3)

tides. Interestingly, exposure of cells to stimuli, such as inter

feron (IFN)-y, tumor necrosis factor (TNF)-0t and
lipopolysaccharide (LPS), induces the synthesis of certain
catalytic subunits (LMP2, MECL-l and LMP7) that together

0

25

30

R I —CH2OH, R' I OH

(4) R I alkyl, R' I C— or O— alkyl groups
(5) R I CH3; R' I OH

are incorporated into alternative proteasome form, knoWn as

the immunoproteasome.

35

The immunoproteasome, as compared to the constitutive
proteasome, has an enhanced capacity to generate peptides

bearing hydrophobic andbasic amino acids at their C-termini,
and a reduced capacity to produce peptides bearing acidic
residues at their C-terminus. Consequently, the spectrum of
the produced peptides is shifted toWards peptides Which asso

40

Anti -tumor natural products epoxomicin (l) and eponemy
cin (2) are members of linear peptides containing ot',[3'-ep

ciate With MHC class I molecules With increased a?inity,

oxyketone pharmacophore and have been shoWn to exert their

implicating a major role in antigen presentation. Immunopro
teasome may be involved in some pathological processes,
such as diabetes and autoimmune diseases. Therefore, devel

opment of immunoproteasome-speci?c inhibitors Would be
useful to investigate the role of immunoproteasome and to
determine Whether immunoproteasome is a potential target

45

anticancer activity through proteasome inhibition. Of par
ticular interest Was the ?nding that, despite structural simi

larities, epoxomicin (l) and dihydroeponemycin (3), an
active derivative of eponemycin, differ in their proteasome
50

subunit binding speci?city.

for development of pharmaceutical agents.
Moreover, unlike other classes of proteasome inhibitors

Scheme 1. ot',[3'-Epoxyketone linear peptide natural products,

epoxomicin and eponemycin, and eponemycin analogues.

55

that shoW non-target speci?city, the epoxyketone proteasome
inhibitor is shoWn to be highly speci?c for the 20S protea
some. The crystal structure of the yeast 20S proteasome com

CH3
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o
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N

O
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60

of epoxyketone pharmacophore is contributed to the forma

cH3

tion of an unusual 6-membered morpholino ring betWeen the

0
0H

amino terminal catalytic Thr-l of the 20S proteasome and the
65

Epoxomicin (l)

plexed With epoxomicin revealed that the unique speci?city

(ot',[3'-epoxyketone pharmacophore of epoxomicin, as shoWn
in the mechanism beloW.
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Epoxomicin (l)
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In addition, it has been shown that dihydroeponemycin (3)
targets the subunits of both constitutive proteasome and

immunoproteasome, Whereas epoxomicin (l) preferentially

Schm“ihs?liii?sgifgiié?t?gggsgmtion of

labels the catalytic subunits of the constitutive proteasome.

'

Recent studies indicated that the ability of dihydroeponemy- 35
cin to bind immunoproteasome subunits is attributed to the P3
isooctanoic moiety of dihydroeponemycin but not the
hydroxyl groups in the P2 and P1‘ positions (see scheme 1).

RHN

H

Therefore, isooctanoic-based dihydroeponemycin analogue
(4) or other dihydroeponemycin analogues having a linear 40

hydrocarbon group at the P3 position may provide an opportunity for the development of immunoproteasome-speci?c
inhibitors. HoWever, a simple and practical approach for the
synthesis of dihydroeponemycin has yet to be developed.
Particularly, the lack of the e?icient synthetic approach for

O7

//

\

\

LiJR

OLi

4s. m

8

the hydroxymethyl-substituted enone motif has been a major

H

obstacle for e?icient synthesis of dihydroeponemycin and
their Pl' derivatives (4).

O

O

Over the years, a number of elegant synthetic strategies for 50

the synthesis of eponemycin and dihydroeponemycin have
been developed. A key step in the synthesis is the preparation

/

\

/

of hydroxymethyl-substituted enone 10 (Scheme 2). In sev
eral earlier approaches, the enone 10 Was prepared from the

reaction of dilithio reagent 8 With the corresponding aldehyde

(Scheme 2). HoWever, loW yields and extra steps involving
protection, oxidation and deprotection of OH groups pre
vented large scale preparation. In similar approaches, the
Weinreb-type amide derivatives treated With dilithio reagent 60
8 did not yield the desired hydroXymethyl-sub stituted enone
10. More recently, neW synthetic approaches have been devel-

OCH3

oped based on the cinchona alkaloid-catalyzed Baylis-Hill
man type reactions that yield the intermediate 7 or Stille 65

coupling of Fmoc-Leu-Cl With n-tributylvinyltin folloWed by

modi?ed Baylis-Hillman reaction (Scheme 2).

OH

9

0

OH
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6
Recently, intense investigation on the role of immunopro
teasome in cells from non-immune system has been initiated
based on a number of studies indicating that immunoprotea
some subunits may be implicated in some pathological pro
cesses, such as hematological cancers, autoimmune diseases

-continued
Li

and neurodegenerative diseases. For example, a high level of
immunoproteasome has been detected in neurodegenerative
human brains, Whereas the human brain has been historically
considered as an immunologically privileged organ. Speci?
cally, it has been shoWn that the immunoproteasome is more
highly expressed in the brains of AlZheimer’s disease (AD)
than in brains of non-demented elderly, Whereas its expres

OLi

BocHN

N/OCH3
\

8

CH3

sion in young brains is negligible or absent. In addition, some

studies indicated that the immunoproteasome may be

involved in Huntington’s disease (HD) neurodegeneration.

//RHN

15

immunoproteasome due to its bone marroW microenviron

ment Where it replicates. Recently borteZomib (VEL
CADE®), the ?rst proteasome inhibitor Was approved by the
FDA for the treatment of multiple myeloma. Despite this
20

these approaches may not be ideal for e?icient derivatiZation
or construction of small library of dihydroeponemycin ana
25

lacking or minimally expressing the immunoproteasome.
Despite the potential role of immunoproteasome in these
pathological disorders, its functions are still not clearly

Over the past decades, the proteasome has emerged as a

understood. Currently, there are no immunoproteasome spe

major player in many important signaling processes such as

ci?c inhibitors Which are therapeutic agents, targeting the
immunoproteasome. Furthermore, the exact role of immuno
proteasome in pathogenesis is not clearly understood, due
largely to the lack of an appropriate molecular probe.
Although some proteasome inhibitors currently exist that
selectively target the immunoproteasome, and a sequence
comparison of catalytic subunits from the constitutive and
immunoproteasomes exhibits a high homology, structural

cell cycle progression, in?ammatory responses and develop
ment. In particular, the fact that the orderly destruction of cell
cycle regulatory proteins is critical to the control of cellular
processes associated With cancer has led to development of
proteasome inhibitors as anti-cancer agents, leading to a

recent FDA approval of the ?rst proteasome inhibitor bor‘t
eZomib for multiple myeloma. Typically, more than 80% of

information about active sites of immunoproteasome are not

cellular proteins are targeted for recognition and subsequent
degradation by the proteasome via the attachment of multiple
ubiquitin molecules.

knoWn to date, hindering prior efforts toWards the design of
immunoproteasome-speci?c inhibitors via rational design
approach, to be therapeutic agents.

The 208 core has a four-stacked ring structure With seven

different subunits in each ring. The tWo inner rings each
contain three catalytically active [3 subunits. The non-cata

remarkable advancement, its clinical use is severely limited

due to drug-related toxicities. Given this, speci?c inhibition
of immunoproteasome should alloW selective killings of mul
tiple myeloma cells While sparing other cells in body that are

However, multiple steps and loW yields associated With

logues for screening immunoproteasome-speci?c inhibitors.

Multiple myeloma is also knoWn to express a high level of

40

Scheme 3. Structures of 0t’, [5’, —epoxyketone linear peptide natural

lytic tWo outer a rings form a gated channel for unfolded

products and dihydroeponemycin analogues. Tripeptide epoxyketones

protein entry and a base for the regulatory complexes (198 or
1 18), Which provide the speci?city of the polypeptide recog

specificity toWards immunoproteasome catalytic subunits than normal
tetrapeptide epoxyketones such as epoxomicin.

nition.
The 208 proteasome has been shoWn to exhibit three major

having a linear hydrocarbon chain at the P3 position has a higher

45

activities: a chymotrypsin-like (CT-L) activity that cleaves

after large hydrophobic residues, a trypsin-like (T-L) activity

CH3

that hydrolyZes after basic amino acids, and a caspase-like
(C-L) activity that cleaves after acidic amino acids. TWo other
less-characterized catalytic activities have also been ascribed
to the proteasome: BrAAP, Which cleaves after branched
chain amino acids, and SNAAP, Which cleaves after small

I

H

N

N

0

_

:

o

O

N

.

N

CH3

o

neutral amino acids. Thus far, While most efforts are directed

to develop proteasome inhibitors against chymotrypsin-like

55

activity, a feW studies have been successful to design inhibi
tors targeting other proteasomal activities, such as caspase

like and trypsin-like activities. Although the CT-L activity of
the proteasome has been shoWn to be largely responsible for
the proteolytic function of the proteasome in vivo and in vitro,
the contribution of other major activities remains to be deter

60

i
:

mined.
While the immunoproteasome is Widely knoWn to play a

major role in MHC class-l antigen presentation, it is believed
not to be solely responsible for antigen presentation as the

constitutive proteasome also generates immunogenic

epitopes.

:lI

Huk
g z
N

0

: g
i =
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H

\OH

Dihydroeponernycin (2)
65

O

N.

0

OH
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8
and (b) adding CH2O and KZO3 to the product of step (a) and
alloWing the reagents to react to produce the hydroxymethyl

-continued

substituted enone,

5

i

:
i

H:
N‘

O

m

0

;

; _

N

:

:

H

i ______________________ __Q____: '

OR’
O

BocNH

Dihydroeponemycin analogues

TWo natural product proteasome inhibitors, epoxomicin
and eponemycin, are members of the ot',[3'-epoxyketone lin

15

ear peptide family. It has been previously shown that, despite

structural similarities, epoxomicin (l) and dihydroeponemy

CH2Cl2 to the hydroxymethyl-substituted enone from step

cin (2), an active derivative of eponemycin, considerably
differ in their proteasome subunit binding speci?city. For

example, dihydroeponemycin preferentially labels the cata
lytic threonine residues of immunoproteasome subunit LMP2

The present method, in a further, speci?c form thereof,

further comprises (c) adding TBDMSCl, lmidaZole and

(b); (d) adding benZonitrile, H2O2, i-Pr2EtN and CH3OH; (e)
20

adding TFA and CH2Cl2; and (f) adding

and to a lesser degree, the constitutive proteasome subunit X

and immunoproteasome subunit LMP7. On the other hand,
NH

epoxomicin covalently modi?es the N-terminus catalytic

OH

threonine residues of both the constitutive proteasome (X &
Z) and immunoproteasome (LMP7 & MECLl) to a similar
extent. It has been shoWn that a relatively higher speci?city of

0

\OTBDPS,

dihydroeponemycin toWards the immunoproteasome sub
units as compared to epoxomicin is due to a linear hydrocar

bon residue at the N-terminus (i.e., isooctanoic group).

30

HBTU, HoBt, i-PRzEtN and CH2Cl2, folloWed by TBAF and
THF to produce dihydroeponemycin,

Recently, it has been shoWn that serine at the P2 site can be

replaced With alanine While maintaining the same subunit

binding pattern as dihydroeponemycin. More interestingly,
careful analysis of other reports indicates that a residue at the
Pl' site may be an important determinant for immunoprotea
some subunit binding.

35

O

MPH

SUMMARY OF THE INVENTION
The present invention is directed to a neW and improved
route to the synthesis of a hydroxymethyl-substituted enone

NH

O

and dihydroeponemycin (3).

H

The present invention is also directed to the synthesis of

proteasome inhibitors that selectively target the immunopro

The present invention, in another form thereof, relates to a

teasome. These proteasome inhibitors comprises a variety of

P1‘ modi?ed dihydroeponemycin analogue comprising

Pl'-modi?ed dihydroeponemycin analogues using easily
available protecting groups. The present dihydroeponemycin
analogues selectively bind to a major immunoproteasome
catalytic subunit LMP2 and inactivate the proteolytic activity
of immunoproteasome With high speci?city. The proteasome
inhibitors are therapeutic agents Which selectively target the
immunoproteasome, and thereby treat diseases, including

O

cancer, AlZheimer’s disease and Huntington’s disease.
The present invention, in one form thereof, relates to a
method for synthesizing a hydroXymethyl-sub stituted enone,

O

comprising (a) reacting Boc-Leu-OMe With dimethyl meth
ylphosphonate treated With tert-butyllithium to form the com

pound,
Where:

R1 is CH3 or CH3OH; and R2 is OH,

BocNH

P\

65

R2,

US 7,642,369 B2
9

10

-continued

-continued

$
In one speci?c compound, R1 is CH3 and R2 is
.

.

.

The present invention, in another form, thereof, relates to a
method for manufacturing a P1‘ modi?ed dihydroeponemy

10

O

cin. analogue, comprising (a) reacting a hydroXymethyl-sub-

/

st1tuted enone,

ii \

15

.

The present invention, in yet another form thereof, relates
to a method of inactivating enzymatic activity of catalytic
subunit LMP2 of the immunoproteasome, comprising react
ing a P1‘ modi?ed dihydroeponemycin analogue,
BocNH

(I)
0

OH,
25

With 2-methoxyethoxymethyl chloride, i-PrZEtN, CH2Cl2;

O

(b) adding benZonitrile, H202, i-PrZEtN, CH3OH; (c) adding
TFA, CH2C12; and (d) adding HBTU, HoBt, i-PrZEtN, 30 W
CH2Cl2, and

NH

0
0

111

R2

Where R1 is CH3 or CH3OH; and R2 is OH,

NHJK
=
OH,

35

5

0

O

NHA

CH3

o
O/\O/,

O/\O/\/ \,
O

40

,

O

|

to produce Pl‘ modi?ed dihydroeponemycin analogue of for-

o

O

I.

/ \

or

Ph/ Sl\Ph

mulal

+i
45

(I)

0

O

With the catalytic subunit LMP2.
The present invention, in anther form thereof, relates to a
method for treating disease by administering to a patient an
effective amount of a dihydroeponemycin analogue having
50 the formula 1

NHA
W
O

=?

NH

(I)

R]

0

R2,
55

Where:

0

R1 is CH3 or CH3OH; and
R2 is OH,

NHA
60 W
5
NH
0
0

O/\O/

O/\O/\/O\

O

65 Where:
R1 is CH3 or CH3OH; and
R2 is OH,

Ii]

0
0

R2,

US 7,642,369 B2
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12
FIG. 2(a) is a Western blot shoWing LMP7/X and LMP2

protein bands are competed aWay by dihydroeponemycin (2)
O

O

and its analogue (9), and FIG. 2(b) is a Western blot shoWing
proteasome subunit (Z, MECLl, LMP7 and X) bands are
e?iciently competed aWay by excess epoxomicin on Western
blot, in accordance With the present invention;
FIG. 3 is a Western blot shoWing compounds 10, 11 and 13

O

O/\O/, O/\O/\/ \, U, or
O

i.

do not selectively target proteasome subunits, and compound

1

14 does not covalently modify proteasome subunits, in accor
dance With the present invention;
FIG. 4(a) is a Western blot depicting compounds 12 and 15

selectively targeting the immunoproteasome subunit LMP2
in EL4 cells, and FIG. 4(b) is a Western blot shoWing com

pounds 12 and 15 do not covalently modify the proteasome
subunits that are normally labeled by epoxomicin, indicating

to bind to the LMP2 subunit of the immunoproteasome,

thereby treating the disease. In various, speci?c further

ing of myeloma, AlZheimer’s disease, and Huntington’s dis

that these compounds do not target subunits such as Z,
MECL-l, LMP7 and X, in accordance With the present inven

ease; and R1 is CH3 and R2 is

tion;

embodiments, the disease is selected from the group consist

FIG. 5 is a Western blot depicting compounds 15 covalently
20

O

modify the immunoproteasome subunit LMP2; and
FIG. 6 is a plot shoWing inhibition of the immunoprotea
some chymotrypsin-like activity by compound 15, in accor

S.

a:

dance With the present invention.
DETAILED DESCRIPTION

25

The present invention is directed to a neW and improved
route to the synthesis of the hydroXymethyl-sub stituted enone

The present invention, in yet another form thereof, relates
to a method of inactivating the immunoproteasome, compris
ing administering to a patient in need of treatment thereof, an
effective amount of a dihydroeponemycin analogue of for

and dihydroeponemycin (3). The hydroxyl group, commonly
30

mula I,

present in both eponemycin and epoxomicin at the P2 posi
tion, is not required for immunoproteasome binding.
In addition, the present invention is directed to a method of

synthesiZing dihydroeponemycin analogues having the gen
(I)

eral formula I
35

(I)
O
O

40

NH

W

5

NH

O

R2,
45

O

0

R2

Where R1 is CH3 or CH3OH; and R2 is OH,
O

Where

O

R1 is CH3 or CH3OH, and
50

O

o/\o/ ,

o/\o/\/ \,
O

O

l

l

l

,

R2 is OH,

l

55

to bind to LMP2 of the immunoproteasome, to thereby inac

60

tivate the immunoproteasome.
BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a Western blot shoWing dihydroeponemycin bind

ing to both constitutive- and immunoproteasome catalytic
subunits, in accordance With the present invention;

65

The present invention is also directed to a method of treat
ment comprising administering to a patient in need to treat
ment thereof, a therapeutically effective amount of a dihy

droeponemycin analogue, having the general formula I, to

US 7,642,369 B2
13
bind to the LMP2 subunit of the immunoproteasome, thereby
treating the disease. The treated diseases include myeloma,

-continued

AlZheimer’s disease, and Huntington’s disease.
The preferred dose for administration of the immunopro
teasome inhibitor, in accordance With the present invention, is
that amount Which Will be effective in preventing or treating
cancer, such as myeloma, AlZheimer’s disease, or Hunting

C
—>

BocHN

ton’s disease, by loWering or inhibiting LMP2 catalytic activ
ity, by binding to the LMP2 subunit, and one Would readily

O

recogniZe that this amount Will vary greatly depending on the

OH

14

nature and extent of the disease and the condition of a patient.
An “effective amount” of the inhibitor to be used in accor
dance With the invention is intended to mean a nontoxic but

suf?cient amount of the agent, such that the desired prophy
lactic or therapeutic effect is produced. Thus, the exact
amount of the inhibitor that is required Will vary from subject
to subject, depending on the species, age, and general condi

tion of the subject, the severity of the condition being treated,
the particular carrier or adjuvant being used and its mode of

d
—>

BocHN
O

20

OTBDPS

15

administration, and the like. Similarly, the dosing regimen
should also be adjusted to suit the individual to Whom the
composition is administered and Will once again vary With

age, Weight, metabolism, etc. of the individual. Accordingly,

25

the “effective amount” of any particular inhibitor Will vary
based on the particular circumstances, and an appropriate
effective amount may be determined in each case of applica
tion by one of ordinary skill in the art using only routine

+

BocHN
O

OTBDPS

30

experimentation.

16

The present method provides an e?icient, practical syn
thetic strategy for the synthesis of hydroxymethyl-sub stituted
enone and dihydroeponemycin. The present method starts

With readily available Boc-Leu-OMe, Which Was prepared

35

from the reaction of Boc-Leu-OH With iodomethane in DMF.

O

The reaction of Boc-Leu-OMe With dimethyl methylphos

BocHN

phonate treated With t-butyllithium yielded compound 13.
Finally, the combination of Wittig-Homer and Baylis-Hill
man type one-pot reactions yielded the hydroxymethyl-sub
stituted enone 14 in high yield (Scheme 4).

6
—>

O
40

OTBDPS

17

Scheme 4. Reagents and conditions: (a) i. CH3PO(OCH3)2, BuLi,
THF, -78° C., 2 h; ii. 12, THF, -78° C., 3 h; (b) CHZO, K2CO3,

O

H2O,1t, 3 h; (c) TBDPSCl, lrnidazole, CHZCIZ, it, 24 h;
(d) Benzonitrile, H202, i—Pr2EtN, MeOH, 0° C., 3 h;
(e) TFA, CHZCIZ, it, 15 min; (f) i. 19. HBTU, HoBt,
i-PrZEtN, CHZCIZ, 1t, 12 h; ii. TBAF, THF,1t, 10 min.
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The synthesis steps for dihydroeponemycin derivatives can

The resulting hydroxymethyl substituted enone Was

treated With TBDPSCl to yield compound 15. Epoxidation of
compound 15 With hydrogen peroxide afforded tWo epoxyke

be further reduced as the serine residue of dihydroeponemy
cin needs to be protected and the alanine residue of its ana
logue does not as shoW in “ToWards lmmunoproteasome

tone isomers 16 and 17 as a 1:15 mixture Which Were readily

separated by ?ash column chromatography using an elution
system (heXanes-ethyl acetate:10: 1, v/v). The isomer (2-(R)
epoxide) 17, Which migrates faster than the 2-(S)-epoxide 16

Speci?c Inhibitors: An Important Synthesis of
Dihydroeponemycin” Abby Ho et al., Eur. .1. Org. Chem.

(2005), herein incorporated by reference.

in thin-layer chromatography (TLC), Was found to have the
same con?guration as that of eponemycin epoxide. The ?nal

The present invention is also directed to the synthesis of

proteasome inhibitors that selectively target the immunopro

coupling reaction betWeen epoxyketone 18 and dipeptide 19
Was performed With HBTU, folloWed by removal of the
TBDPS group and normal phase HPLC (heXanes-isopro
panol, linear gradient, hexanes 100% to 50%) to yield dihy

teasome. These proteasome inhibitors comprises a variety of

P1'-modi?ed dihydroeponemycin analogues using easily
available protecting groups (Scheme 6).

droeponemycin (3).
As compared to prior art methods of synthetic strategies,
the combination of Wittig-Horner and Baylis-Hillman type
tWo-step “one-pot” reaction presented here is ef?cient and

5

practical for a large quantity preparation, easily providing the
key intermediate, hydroxymethyl-substituted enone, in a
multi-gram scale. The one-pot reaction may be rationaliZed

20

by the folloWing mechanistic consideration (Scheme 5).

Scheme 5.
Mechanistic consideration for the one-pot reaction that may occur

sequentially through the Wittig-Homer and Baylis-Hillman type reactions.
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Scheme 6.

Synthetic scheme of dihydroeponernycin analogues. Reagents and conditions for 12.
(a) 2-Methoxyethoxyrnethyl Chloride, i—Pr2EtN, CHZClZ, 0° C. —> rt;

(b) Benzonitrile, H202, i-PrZEtN, CH3OH, 0° C., 3 h; (c) 5, TFA, CHZClZ, 30 rnin;
(d) 7, HBTU, HoBt, i-PrZEtN, CHZClZ, rt, 12 h; (e) TBAF, THF, 1 h.
*(e) precedes (d): 7 Was deprotected With TBAF before coupled to 6.
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The present dihydroeponemycin analogues selectively
dihydroeponemycin, in Which the P2 serine of eponemycin is
bind to a major immunoproteasome catalytic subunit LMP2 25 replaced With alanine, displayed a non-speci?c proteasome
and inactivate the proteolytic activity of immunoproteasome
subunit binding pattern similar to that of dihydroeponemycin.
With high speci?city.
Similar competition assays Were performed to screen for
To test the speci?city of binding of the present dihydroeimmunoproteasome inhibitors in a EL4 cell model system.
ponemycin analogues, a screening assay Was developed for 30 EL4 cell system Was chosen since these cells highly express
immunoproteasome subunit speci?c compounds Biotincatalytic subunits of both the constitutive and immunoprotea
tagged epoxomicin and dihydroeponemycin Were used as
SOIneS.
assay probes With Which to perform screening assay for
Given the previous studies suggesting that the N-terminus

immunoproteasome

subunit-speci?c

compounds.

The

hydrocarbon group plays an important role in targeting the

screening assay Was ?rst veri?ed by using epoxomicin, dihy- 35 immunoproteasome (29), the present inhibitors Were devel
droeponemycin and eponemycin analogue Whose proteaoped based on the derivatiZation at the C-terminal hydroxyl
some subunit binding patterns are Well knoWn from Kim, K.
group (Scheme 6). First, methoxymethyl ether (MOM) group
B., Myung, 1., Sin, N., and CreWs, C. M. “Proteasome inhiWas added, preparing compounds 11 and 14. This replace
bition by the natural products epoxomicin and dihydroeponement caused a dramatic loss in the potency and speci?city

mycin: insights into speci?city and potency,” Bioorg. Med. 40 compared to dihydroeponemycin (FIG. 3). Similarly, dihy
Chem. Lett. 9, 3335-3340 (1999) (herein incorporated by
droeponemycin analogues With a bulky tert-butyldiphenylsi
reference); and “ToWards lmmunoproteasome-Speci?c
lyl (TBDPS) group (10) or tetrahydropyranyl (THP) group
Inhibitors: An Improved Synthesis of Dihydroeponemycin.”
(13) lost its activity against the immunoproteasome (FIG. 3).
Speci?cally, various concentrations of these compounds Were
strikingly, When the MOM group Was replaced With meth
pre-incubated in EL4 cells at 37° C.for 30 min. Biotin-tagged 45 oxyethoxymethyl (MEM) ether group (12), Which has a
dihydroeponemycin or ePOXOmiCin Were then added and
longer linear group than the MOM group, high speci?city
incubated for an additional hour at 37° C. After cells Were

towards LMP2 Was achieved (upper panel Of FIG 40;»

lysed, Whole Cell lysates Were analyzed using 12% SDS'
PAGE and transferred to PVDF membranes. Biotinylated

lntriguingly,Whenthebulky TBDPS group Was replacedWith
a less bulky terpbutyldimethyls?yl (TBDMS) group (15), an

proteins Were then visualiZed using streptavidin-horseradish 50 even highgr Speci?city towards the LMP2 Subunit Was

P?roxid?1S6 (HRP) and enhanced Chemiluminescence (ECL)-

obtained, as shoWn in FIG. 4(a) (loWer panel). Preincubation

Referring to FIG. 2(a), a Western blot Which shoWs
LMP7/X and LMP2 protein bands are competed aWay by

of EL4 cells With 1 uM of compound 15 (one equivalent of
assay probe) Was suf?cient to selectively modify the catalytic

dihydroeponemycin (2) and its analogue compound 9. FIG.

threonine residue of LMP2 subunit, thereby preventing fur

2(b) is a Western blot Which shoWs proteasome subunit (Z, 55 ther modi?cation of LMP2 subunit by biotin-dihydroepone

MECLl, LMP7 and X) bands are ef?ciently competed aWay

mycin, resulting in selective attenuation of LMP2 protein

by excess epoxomicin. The Western blots Were performed

band on Western blot. Experiments With another assay probe

using EL4 cells pre-incubated With proteasome inhibitors for
(biotin-epoxomicin), Which normally labels proteasome sub
30 min before treating With biotinylated compounds. After 1
units LMP7, X, MECL-l and Z, further supported that both
hr incubation, cells Were lysed, and analyZed by Western blot 60 compounds 12 and 15 speci?cally target LMP2 subunit but
using streptavidin-HRP and ECL.
not other proteasome subunits (FIG. 4(b)). These results fur
All of biotinylated proteasome subunit bands Were equally
competed aWay With excess dihydroeponemycin, its analogue or epoxomicin. These results con?rm that both

ther Con?rm that Compounds 12 and 15 are Speci?c LMP2
inhibitors
The mobility shift of LMP2: l5 adduct Was investigated to

epoximicin and dihydroeponemycin do not have speci?city 65 further verify that compound 15 covalently modi?es the
toWards subunits of either the constitutive or immunoproteasomes. In addition to these tWo compounds, an analogue of

LMP2 subunit (FIG. 5). After EL4 cells Were incubated With
compound 15 or assay probes (Biotin-EPX and Biotin-EPN)

US 7,642,369 B2
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for 1 hr at 370 C., cells Were lysed and boiled for 15 min.

provide evidence that compound 15 is a highly speci?c
immunoproteasome inhibitor that selectively inactivates the

Whole cell proteins Were then analyzed by Western blot using
anti-LMP2 antibody. In this experiment, biotinylated epoxo

LMP2 subunit.

In conclusion, the present epoxyketone-pharrnacophore

micin (Biotin-EPX) and dihydroeponemycin (Biotin-EPN)

based selective LMP2 inhibitors inhibit the catalytic function

Were used as controls that induce LMP2 mobility shift.
Since molecular Weights of the LMP2 subunit are

of immunoproteasome With high speci?city. In addition, the
LMP2 inhibitors inactivate the proteolytic activity of 20S

increased by 828.08 (for biotin-epoxomicin) and 1078.45 (for

immunoproteasome With high speci?city.

biotin-dihydroeponemycin), assay probe-LMP2 adducts are

The signi?cance of the aforementioned experiments pro

expected to shoW a sloWer mobility as compared to free

vides evidence that the present inhibitors represent a class of

LMP2 (lanes 1-3, FIG. 5). While a sloWer mobility for the

inhibitors Which can be used as a therapeutic agent to treat

LMP2-15 adduct on SDS PAGE Was clearly shoWn as com

diseases related to the immunoproteasome. The immunopro

pared to free LMP2 (lanes 4 and 5), its mobility shift Was
smaller than those of assay probe-LMP2 adducts (lane 3 vs.
lane 4). It can be explained by a smaller molecular Weight of

teasome has been implicated in a number of disease states.

The immunoproteasome speci?c inhibitors described herein
provide a therapeutic agent for hematological cancers, such

compound 15 (484.76) compared to assay probes (828.08 and
1078.45). Interestingly, 1 uM of compound 15 but not assay

as multiple myeloma, and autoimmune diseases and neuro
degenerative diseases such as Alzheimer’s disease and Hun
tington’s disease, as Well as provide a useful molecular probe

probes Was su?icient to modify LMP2 subunits present in
cells (lanes 2 & 3 vs 4). This strongly indicates that compound
15 modi?es the LMP2 subunit more e?iciently than tWo assay

to investigate the immunoproteasome biology.
20

probes. LMP2 inhibitor e?iciently blocks the proteolytic
activity of immunoproteasome With high speci?city. Screen
ing assay and mobility shift studies have shoWn that com
pound 15 selectively inactivates the LMP2 subunit via cova
lent modi?cation. Since LMP2 is a major catalytic subunit

25

responsible for chymotrypsin-like activity, inactivation of the
LMP2 subunit inhibits proteolytic activity of immunoprotea
some. Con?rmation of this is provided by enzyme kinetics

studies performed using puri?ed 20S immunoproteasome.
Enzyme kinetics experiments Were also carried out With the
puri?ed 20S constitutive proteasome as control.

30

To compare the e?icacy of the present LMP2 inhibitor
compounds and, in particular, LMP2 inhibitor 15, as com
pared to prior knoWn inhibitors, comparative tests Were con
ducted using compound 21 in expressing tumor cells. LMP2
inhibitor compound 21 blocked proliferation of lung cancer
H460, prostate cancer cells PC3 and multiple myeloma cells
RPMI8226, as summarized in Table 2, beloW. Western blot
analysis shoWed that the LMP2 immunoproteasome subunit
is expressed in these cell lines. Therefore, the LMP2 inhibitor
compounds of the present invention, based on these results,
summarized in Tables 1 and 2, provide better or superior
blocking of cell proliferation in cancer cells than prior LMP2
inhibitor compounds. Thus, the present LMP2 inhibitors pro

vide superior therapeutic agents against diseases such as
myeloma, Alzheimer’s disease and Huntington’s disease.

TABLE 1
Inhibition of chymotrypsin-like activity of the 20S constitutive and

35

immunoproteasomes by compound 15.

TABLE 2
Cell proliferation assays Were performed by counting

208 regular

20S

Relative

Compounds

proteasome

immunoproteasome

selectivityC

Epoxomicin

44,510 r 7,000

3,044 r 1,423

1

(25-75 11M)b

(100-400 11M)

Dihydroeponemycin
Compound

15

721 r 84

251 r 121

(0.25-5 pM)

(0.5-3.0 11M)

49 r 18

83 r 27

(10-50 11M)

(5-20 pM)

cell numbers after 24 h incubation With compound 21,

1C MUM)
WI-38

5
24

dihydroeponemycin or epoxomicin

40

Cell line

H460 (Lung)

45 Compound
21

Epoxomicin

“See Experimental Procedures for details.
Z’Values in parentheses indicate the range of inhibitor concentrations used.

5
0.1

(Fibroblast)
12.8
0.028

RPMI8226

PC3 (Prostate)

(MM)

1.6

2.5

0.01

0.1

CRelative selectivity = immunoproteasome/regular proteasome. Values are

normalized against that of epoxomicin

50

The folloWing experiments Were conducted to demonstrate

Enzyme kinetics Were performed by measuring the chy
motrypsin-like activity of 20S immunoproteasome and regu

the effectiveness of the present synthesis methods for produc

ing the dihydroeponemycin analogues. Unless otherWise

lar proteasome in the presence of compound 15 using a ?uo

rogenic peptide substrate. Although compound 15 poorly
inhibited the chymotrypsin-like activity of 208 regular pro
teasome, it displayed a better inhibitory activity against the
immunoproteasome. This is quite unusual and surprising,

stated, all reactions Were carried out under nitrogen With dry
55

chloride (CH2Cl2) Was distilled from calcium hydride.
Diethyl ether anhydrous Was purchased from EMD Chemi
cals and used Without further puri?cation. All reagents Were

purchased from Sigma-Aldrich and used Without further puri
?cation. All reactions Were monitored by thin layer chroma

parison to epoxomicin and dihydroeponemycin, respectively

tography (TLC) using E. Merk 60F254 pre-coated silica gel

(Table 1).
tion-dependent inhibition against the chymotrypsin-like
activity of 20S immunoproteasome. All together, these results

freshly distilled solvents, oven-dried glassWare and magnetic
stirring. All solvents Were reagent graded. Tetrahydrofuran
(THF) Was distilled from sodium/benzophenone. Methylene

considering most of proteasome inhibitors inhibit the consti
tutive proteasome better than the immunoproteasome. More
speci?cally, compound 15 displayed a 24-fold and 5-fold
higher selectivity toWard the 20S immunoproteasome in com

Referring to FIG. 6, FIG. 6 shoWs a time- and concentra

Experiments

65

plates. Flash column chromatography Was performed using
E. Merk silica gel 60 (particle size 0.040-0.063 mm) and With
the indicated solvents. 1H and Was recorded in CDCl3 using a
Varian 300 MHz spectrometer at ambient temperature using

US 7,642,369 B2
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an internal deuterium lock unless stated otherwise. Chemical
shift are referenced to residual chloroform (6:7.27 ppm for

yielded compound 7 as yelloWish oil. 1H NMR: 6:7.61 (m,

sentative synthetic procedure for all dihydroeponemycin ana
logues and, as described in “Development of the lmmunopro

4H, AriH), 7.41 (m, 6H, AriH), 6.24 (d, 21:75 HZ, 1H,
NH), 4.69 (m, 1H, 2-H), 4.17 (dd, 21:104 HZ, 21:36 HZ,1H,
3-H“), 3.89 (dd, 21:104 HZ, 21:36 HZ, 1H, 3-Hb), 2.20 (t,
31:75 HZ, 2H, 2'-H), 1.60 (m, 2H, HHeP), 1.29 (m, 6H, HHeP),
1.05 (s, 9H, Hbutyl), 0.88 (t, 31:69 HZ, 3H, 7'-CH3) ppm.

teasome-Speci?c Inhibitors,” Abby Ho and Kyung-Bo Kim,
[Journal Name] (200_), herein incorporated by reference.

seryl methyl ester: tert-Butyldiphenylsilyl chloride (1.95 ml,

1H). High and loW resolution mass spectra Were carried out by

the University of Kentucky Mass Spectrometry Facility.
Synthesis of compound 12 is described here as the repre

(S)iO-tert-Butyidiphenylsiloxymethyl-N-heptanoyl
7.6 mmol), imidaZole (519 mg, 7.6 mmol) Was added to a

Such analogues include those of formula (I).

solution of (S)-N-heptanoyl-serine methyl ester (588.6 mg,
2.5 mmol) in CH2Cl2 (20 ml) and stirred overnight at room

(4S)-4-(tert-butoxycarbonyl)-amino-2-hydroxy-methyl
6-methylhept-1-en-3-one (3): Synthetic procedures Were per
formed as previously reported in Fruh, K., Gossen, M., Wang,
K., Bujard, H., Peterson, P. A., and Yang, Y. (1994), herein

temperature. The resulting mixture Was concentrated under
reduced pressure and subjected to column chromatography

(hexane/EtOAc, 5:1) yielding (S)4O-tert-Butyldiphenylsi

incorporated by reference. Displacement of housekeeping

loxymethyl-N-heptanoyl-seryl methyl ester (890 mg, 74%)

proteasome subunits by MHC-encoded LMPs: a neWly dis
covered mechanism for modulating the multicatalytic pro
teinase complex. Embo. J. 13, 3236-3244.

as colorless oil. 1H NMR: 6:7.59 (m, 4H, AriH), 7.41 (m,

(4S)-4-(tert-Butoxycarbonyl)-amino-2-(methoxy
ethoxymethoxymethyl)-6-methylhept-1-en-3-one (4): To a

20

solution of compound 3 (114 mg, 0.42 mmol) in CH2Cl2 (5

HHeP), 1.04 (s, 9H, Hbmyl), 0.88 (t, 31:67 HZ, 3H, 7'-CH3)

ml) at 0° C. Was added methoxyethoxymethyl chloride (0.24

ppm

ml, 2.1 mmol) and diisopropylethylamine (0.37 ml, 2.1
mmol). After stirring at room temperature for 3 h, the result
ing mixture Was pour into ice Water (20 ml) and extracted With

(S)iN-heptanoyl-serine methyl ester: To a solution of
25

mmol), HOBt (0.74 g, 4.8 mmol) and lastly diisopropylethy

Washed With brine (20 ml), dried With Na2SO4, ?ltered and

lamine (2.8 ml, 16 mmol). Reaction Was stirred overnight at

concentrated under reduced pressure. The product Was then

HZ, 1H, NH), 5.03 (m, 1H, 4-H), 4.75 (s, 2H, 2-OCH2O), 4.28
(s, 2H, 2-CH2), 3.69 (m, 2H, 2-OCH2CH2O), 3.55 (m, 2H,
2-OCH2CH2O), 3.38 (s, 3H, 2-OCH3), 1.74 (m, 1H, 6-H),
1.50 (m, 1H, 5-H“), 1.41 (s, 9H, HBOC), 1.31 (m, 1H, 5-Hb),
0.99 (d, 31:66 HZ, 3H, CH3CHCH3), 0.90 (d, 31:66 HZ, 3H,

room temperature. The resulting mixture Was subjected to
30

?ash column chromatography (hexane/EtOAc, 1:2) yielding
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yelloWish oil. 1H NMR: 6:6.47 (b, 1H, NH), 4.69 (m, 1H,
2-H), 3.94 (m, 2H, 3-H), 3.79 (s, 3H, 1-OCH3), 2.27 (t, 31:76
HZ, 2H, 2'-H), 1.63 (m, 2H, HHeP), 1.29 (m, 6H, HHeP), 0.88
(m, 3H, 7'-CH3) ppm.

(S)iN-heptanoyl-serine methyl ester (588.6 mg, 79%) as

(4S)-2-methoxyethoxy-methoxymethyl-4-[(S)iO-tert
butyidiphenylsiloxy-methyl-N-heptanoylseryl-amino] -6
methyl-1,2-oxiranyl-heptane: Tri?uoroacetic acid (100 pl,

CH3CHCH3) ppm.

(2RS,4S)-4-(tert-Butoxycarbonyl)-amino-2-(methoxy
ethoxymethoxymethyl)- 6-methyl -1 ,2 -oxiranyl-heptane (5,
5'): BenZonitrile (0.29 ml, 2.8 mmol), H2O2 (0.40 ml, 50%

0.87 mmol) Was added to a solution of compound 5 (45 mg,
40

solution in H2O, 7.0 mmol) and diisopropylethylamine (0.5

45

centrated under reduced pressured and subjected to ?ash col
umn chromatography (hexane/EtOAc, 10:1) to yield com
pounds 5 and 5' With a ratio of 3:1 (60 mg, 60%). Compound

5: 1H NMR: 6:4.82 (d, 21:84 HZ, 1H, NH), 4.71 (s, 2H,
2-OCH2O), 4.39 (d, 2J:11.4 HZ, 1H, 2-CH“2), 4.32 (m, 1H,
4-H), 3.68 (m, 2H, 2-OCH2CH2O), 3.57 (m, 2H,
2-OCH2CH2O), 3.49 (d, 2J:11.4 HZ, 1H, 2-CHZ’2), 3.40 (s,
3H, 2-OCH3), 3.27 (d, 21:48 HZ, 1H, 1-H“), 3.03 (d, 21:48
HZ, 1H, l-Hb), 1.75 (m, 1H, 6-H), 1.58 (m, 1H, 5-H“), 1.41 (s,
9H, HBOC), 1.13 (m, 1H, 5-H°), 0.97 (d, 31:66 HZ, 3H,
CH3CHCH3), 0.94 (d, 31:66 HZ, 3H, CH3CHCH3) ppm.

lamine (104 pl, 0.59 mmol). Reaction Was stirred overnight at
room temperature. The resulting mixture Was subjected to
50

(4S)-2-methoxyethoxy-methoxymethyl-4-[(S)4O-tert-bu
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heptanoyl-seryl methyl ester (890 mg, 1 .8 mmol) in methanol
Water (3:1) solution. Reaction Was stirred at 50 C. for 15 h.

Resulting mixture Was poured into H2O With cold 1N HCl and

Washed With brine, dried under Na2SO4, ?ltered, concen
trated and dried under high vacuum. The product obtained

?ash column chromatography (hexane/EtOAc, 3:1) to give
tyldiphenylsiloxy-methyl-N-heptanoylseryl-amino] -6-me
thyl-1,2-oxiranyl-heptane (36 mg, 42%). 1H NMR: 6:7.71

(S)iO-tert-Butyidiphenylsiloxymethyl-N-heptanoyl

extracted With CH2Cl2. The organic layers Were combined,

folloWing coupling reaction Without further puri?cation. To a
solution ofproduct 6 (33 mg, 0.12 mmol) and 7 (65 mg, 0.14
mmol) in CH2Cl2 (5 ml) Were added HBTU (68 mg, 0.17

mmol), HOBt (27 mg, 0.17 mmol) and lastly diisopropylethy

serine (7): Lithium hydroxide (91 mg, 3.8 mmol) Was added
to a solution of (S)4O-tert-Butyldiphenyl-siloxymethyl-N

0.12 mmol) in CH2Cl2 (0.5 ml) at room temperature for 30
min. Subsequently, the concentrated mixture Was dried under
high vacuum to remove tri?uoroacetic acid. The resulting
crude product 6 (33 mg, ca. 100%) Was then used in the

ml, 2.8 mmol) Were added to a solution of compound 4 (100
mg, 0.28 mmol) in MeOH (5 ml) at 0° C. The reaction Was
stirred at 0° C. for 3 h. The resulting mixture Was then con

heptanoic acid (0.46 ml, 3.2 mmol) and H-Ser-OCH3 (0.5 g,
3.2 mmol) in CH2Cl2 (15 ml) Were added HBTU (1.83 g, 4.8

CH2Cl2 (3x20 ml). The organic layers Were combined,
subjected to ?ash column chromatography (hexane/EtOAc,
5:1) yielding compound 4 (101 mg, 67%) as a yelloWish oil.
1H NMR: 6:6.20 (d, 21:318 HZ, 2H, 1-H), 5.12 (d, 21:90

6H,AriH), 6.28 (d, 21:84 HZ, 1H, NH), 4.70 (m, 1H, 2-H),
4.12 (dd, 21:101 HZ, 21:30 HZ, 1H, 3-H“), 3.89 (dd, 21:101
HZ, 21:30 HZ, 1H, 3-Hb), 3.74 (s, 3H, 1-OCH3), 2.11
(t, 3J:7.7 HZ, 2H, 2'-H), 1.57 (m, 2H, HHeP), 1.30 (m, 6H,
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(m, 4H,AriH), 7.44 (m, 6H,AriH), 7.02 (d, 21:84 HZ, 1H,
4-NH), 6.17 (d, 21:66 HZ, 1H, 2'-NH), 4.72 (s, 2H,
2-OCH2O), 4.60 (m, 2H, 4-H, 2'-H), 4.42 (d, 21:1 1 .4 HZ, 1H,
2-CHa2), 4.03 (m, 1H, 3'-H“), 3.70 (m, 3H, 3'-CH°2,
2-OCH2CH2O), 3.55 (m, 2H, 2-OCH2CH2O), 3.52
(d, 2J:11.4 HZ, 1H, 2-CHb2), 3.40 (s, 3H, 2-OCH3), 3.29
(d, 21:54 HZ, 1H, 1-H“), 3.04 (d, 21:48 HZ, 1H, l-Hb), 2.13
(t, 31:76 HZ, 2H, 2"-H), 1.63 (m, 4H, 6-H, 5-H“, HHeP), 1.26
(m, 6H, HHeP), 1.07 (s, 9H, 3'-tBu), 0.96 (d, 31:63 HZ, 3H,
CH3CHCH3), 0.91 (d, 31:63 HZ, 3H, CH3CHCH3), 0.86
(t, 3J:7.6 HZ, 3H, 7"-CH3) ppm.

(4S)-2-methoxyethoxymethoxymethyl-4-N-hep
tanoylserylamino-6-methyl-1,2-oxiranylheptane (12): To a
solution of (4S)-2-methoxyethoxy-methoxymethyl-4-[(S)i
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amino]-6-methyl-1,2-oXiranyl-heptane (30 mg, 0.042 mmol)
in THF (1 ml), tetrabutylammonium ?uoride (50 ul, 1 M in
THF, 0.05 mmol) Was added. Reaction Was stirred at room

temperature for 1 hour, followed by ?ash column chromatog

/OCH3

raphy (heXane/EtOAc, 1:2) yielding compound 12 (16 mg,
80%) as yellowish oil. 1H NMR: 6:6.83 (d, 2J:7.5 HZ, 1H,

and

4-NH), 6.44 (d, 21:75 HZ, 1H, 2'-NH), 4.71 (s, 2H,
2-OCH2O), 4.50 (m, 2H, 4-H, 2'-H), 4.41 (d, 21:1 1.7 HZ, 1H,
2-CH“2), 4.08 (m, 1H, 3'-H“2), 3.68 (m, 2H, 2-OCH2CH2O),
3.55 (m, 3H, 2-OCH2CH2O, 3'-Hb2), 3.46 (d, 21:1 1 .7 HZ, 1H,
2-CHb2), 3.40 (s, 3H, 2-OCH3), 3.27 (d, 2J:5.1 HZ, 1H,
1-H“), 3.05 (d, 21:48 HZ,1H, l-Hb), 2.22 (m, 2H, 2"-H), 1.60
(m, 4H, 6-H, 5-H“, HHeP), 1.28 (m, 6H, HHeP), 0.96 (d, 31:39
HZ, 3H, CH3CHCH3), 0.94 (d, 31:39 HZ, 3H, CH3CHCH3),
0.88 (t, 31:67 HZ, 3H, 7"-CH3) ppm. MS (ESI): m/Z:475,

O

(b) adding CH2O and K203 to the product of step (a) and
alloWing the reagents to react to produce the hydroxym
ethyl-sub stituted enone,

calcd. for C23H42N2O8: m/Z:474.59.
Cell Culture and Screening As say: Murine lymphoma EL4
(ATCC) cells Were groWn in RPMI medium (Gibco), 10%
fetal bovine serum and 1% penicillin and streptomycin at 00
C. in a 5% CO2 incubator. Cells Were pretreated With 1 uM

BocNH
20

O

biotinylated compounds 30 minutes prior to the addition of
increasing concentrations of either dihydroeponemycin,
epoxomicin or dihydroeponemycin analogues as indicated.

2. The method of claim 1, Wherein said step (a) comprises

cooling dimethyl methylphosphonate treated With tert-butyl
lithium in THF at —780 C. prior to adding the Boc-Leu-OMe.
3. The method of claim 1 further comprising:

The cells Were then incubated for an additional 1 hour. Cell

lysates Were analyZed by 12% SDS-PAGE and transferred to
PVDF membrane. Proteins that Were covalently modi?ed by
biotinylated compounds Were visualiZed by enhanced chemi

(c) adding TBDMSCl, ImidaZole and CH2Cl2 to the
hydroxymethyl-substituted enone from step (b);

(d) adding benZonitrile, H202, i-PrzEtN and CH3OH;

luminescence using streptavidin conjugated horseradish per
oxidase

(Sigma-Aldrich)

or

anti-LMP2

(A?inity

OH.
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BioReagents) and Biomax X-ray ?lm (Kodak).

(e) adding TFA and CH2Cl2;

(f) adding

Enzyme Kinetic Studies: kaSSOcZ-an-On values Were determined
as folloWs. Inhibitors Were mixed With a ?uorogenic peptide

substrate and assay buffer [20 mM Tris (pH 8.0), 0.5 mM
EDTA, and 0.035% SDS] in a 96-Well plate. The chymot

35

NH

rypsin-like activity Was assayed using the ?uorogenic peptide
substrates Suc-Leu-Leu-Val-Tyr-AMC (Sigma-Aldrich).
HydrolysisWas initiated by the addition of bovine 20S pro
teasome or immunoproteasome (Biomol International), and
the reaction Was folloWed by ?uorescence (360-nm excita
tion/460-nm detection) using a Microplate Fluorescence

OH
0

HBTU, HoBt, i-PR2EtN and CH2Cl2, folloWed by TBAF
and THF to produce dihydroeponemycin,

Reader (FL600; Bio-Tek Instruments, Inc., Winnoski, Vt.)
employing the softWare KC4 v.2.5 (Bio-Tek Instruments,
Inc., Winooski, Vt.). Reactions Were alloWed to proceed for

\OTBDPS,

40
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60-90 min, and ?uorescence data Were collected every 1 min.
Fluorescence Was quanti?ed as arbitrary units and progres
sion curves Were plotted for each reaction as a function of

time. kobserved/[l] values Were obtained using PRISM pro
gram by nonlinear least squares ?t of the data to the folloWing

equation:

NH
50

O

?uorescenceqlst+[(vo—vs)/kobserved]

[1-exp(—k0bserved t)], Where v0 and vs are the initial and ?nal
velocities, respectively, and kobserved is the reaction rate con
stant. The range of inhibitor concentrations tested Was chosen
so that several half-lives could be observed during the course

55

OH.

4. The method of claim 3, Wherein said step (f) comprises

adding

of the measurement. Reactions Were performed using inhibi
tor concentrations that Were <100-fold of those of the protea
some assayed.

NH
OH

The invention claimed is:
1. A method for synthesizing a hydroXymethyl-sub stituted

0

enone, comprising the steps:

(a) reacting Boc-Leu-OMe With dimethyl methylphospho
nate treated With tert-butyllithium to form the com

pound,

\OTBDPS,

65

HBTU, HoBt, i-PR2EtN and CH2Cl2 at room temperature for
12 hours before adding the TBAF and THF.
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5. A Pl‘ modi?ed dihydroeponemycin analogue compris
ing a compound having the structure of formula I,
o

o

(I)

5

a

O

a

a

O/\O/ O/\O/\/ \ U

o

NWNHA
=

o

NH

10

=

0

O

ii

ii

/ \, or Ph/ \Ph

R1

Where:
R1 is CH3 or CH3OH; and

O

0

R2,

+

+I

15

R2 is OH,

7. The method of claim 6, further comprising (e) prior to
step (d), adding TBAF and THF to the product of step (c).
O
7

O

OAO/ O/\O/\/ \
O

O

i-

'

l

O

7

8. A method for treating disease by administering to a
,

~

~

~

.

20 patient an effective amount of a dihydroeponemycm ana
logue having the formula I,

/ \. or Ph/ \Ph

-

<1)
25

6. A method for manufacturing a P1‘ modi?ed dihydroe-

O

ponemycin analogue, comprising:

O

NHA

(a) reacting a hydroxymethyl-substituted enone,

30

ANY

5

0

NH

Ii}

0

R2,

Where:

35

BocNH
0

with

R1 is cH3 or CH3OH; and
R2 is OH’

OH,

2-Methoxyethoxymethyl

chloride,

i-PrZEtN, 40

CH2Cl2, from 0° C. to rt;

O
,

(b) adding benZonitrile, H202, i-PrZEtN, CH3OH;

O

,

O
,

O/\O/ O/\O/\/ \

(c) adding TFA, CH2Cl2; and
(d) adding HBTU, HoBt, i-PrZEtN, CH2Cl2; and
45

O
NH

O

O

i

L

l

1

/ \, Or Ph/ \Ph,
5

0H,

0

50

to produce P1‘ modi?ed dihydroeponemycin analogue’
havmg formula I

to bind to the LMP2 subunit of the immunoproteasome,
thereby treating the disease.

(I) 55

9. The method of claim 7, wherein R1 is CH3 and R2 is
O

o

A

|

NH

W
0
Where:

R1 is CH3 or CH3OH; and

R2 is OH,

Zen- u

NH 0

O

60

R2,

+
65

10. The method of claim 7, Wherein the disease is selected

from the group consisting of myeloma, AlZheimer’s disease,
and Huntington’s disease.
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Where:

11. The method of claim 9, wherein R1 is CH3 and R2 is

R1 is CH3 or CH3OH; and
R2 is OH

O
Si

5

0

o

O/\O/ O/\O/\/ \ U
a

O

o

0

S1

S1

a

,

12. The method of claim 8, Wherein said administering

comprising administering the dihydroeponemycin analogue
via intravenous administration.

13. A method of inactivating enzymatic activity of the
LMP2 subunit of the immunoproteasome, comprising:

15

administering to a patient in need of treatment thereof, an
effective amount of a dihydroeponemycin analogue of

to bind to LMP2 of the immunoproteasome, to thereby

formula I,

inactivate the immunoproteasome.
14. The method of claim 13, wherein R1 is CH3 and R2 is

O
O

NH

WY
0

as, or Plx’h,

26-ml

NH
O

R2,
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